Similar findings were also presented by a research on bone-cancer induced pain (BCP), showing that downregulation of ANXA3 using shRNA substantially inhibited the expression of HIF1α and VEGF in the ipsilateral spinal cord and microglial cells of mice undertaken 21 days of bone cancer induction (Zhang Z. et al., 2020). This evidence concerns the gene ANXA3 and bone cancer.